Cabaletta Bio Inc.

1.20
-0.04 (-3.23%)
At close: Apr 03, 2025, 3:59 PM
1.23
2.92%
After-hours: Apr 03, 2025, 06:47 PM EDT

Company Description

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.

The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.

Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris.

It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California.

The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.

Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio Inc.
Cabaletta Bio Inc. logo
Country United States
IPO Date Oct 25, 2019
Industry Biotechnology
Sector Healthcare
Employees 161
CEO Dr. Steven A. Nichtberger M.D.

Contact Details

Address:
2929 Arch Street
Philadelphia, Pennsylvania
United States
Website https://www.cabalettabio.com

Stock Details

Ticker Symbol CABA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001759138
CUSIP Number 12674W109
ISIN Number US12674W1099
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Dr. Steven A. Nichtberger M.D. Co-Founder, Chairman, Chief Executive Officer & President
Dr. Aimee Payne M.D., Ph.D. Co-Founder & Co-Chair of Scientific Advisory Board
Dr. Gwendolyn K. Binder Ph.D. President of Science & Technology
Dr. Michael C. Milone M.D., Ph.D. Co-Founder & Co-Chair of Scientific Advisory Board
Dr. Samik Basu M.D. Chief Scientific Officer
Gerwin Winter M.B.A., Pharm.D. SVice President & Head of International
Heather Harte-Hall M.Sc. Chief Compliance Officer

Latest SEC Filings

Date Type Title
Mar 31, 2025 S-8 Filing
Mar 31, 2025 POS AM Filing
Mar 31, 2025 10-K Annual Report
Mar 31, 2025 POSASR Filing
Mar 31, 2025 8-K Current Report
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing
Mar 04, 2025 4 Filing